Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 2939850-17-4
2. Balomenib [inn]
3. 3beg4bwn8e
4. Schembl30405225
5. Gtpl13734
6. Bdbm742485
7. Ex-a12708
8. Us20250163061, Compound 102
9. Ze63-0302
10. 1h-indole-2-carbonitrile, 4-methyl-1-[[(2s)-5-oxo-2-morpholinyl]methyl]-5-[[2-[6-(2,2,2-trifluoroethyl)-4-quinazolinyl]-2,7-diazaspiro[3.5]non-7-yl]methyl]-
11. 4-methyl-1-[(2s)-5- Oxomorpholin-2- Yl]methyl]-5- [[2-[6-(2,2,2- Trifluoroethyl) Quinazolin-4-yl]-2,7- Diazaspiro[3.5]nonan- 7-yl]methyl]indole-2- Carbonitrile Example 46
12. 4-methyl-1-[[(2s)-5-oxomorpholin-2-yl]methyl]-5-[[2-[6-(2,2,2-trifluoroethyl)quinazolin-4-yl]-2,7-diazaspiro[3.5]nonan-7-yl]methyl]indole-2-carbonitrile
13. 4-methyl-1-{[(2s)-5-oxomorpholin-2-yl]methyl}-5-({2-[6-(2,2,2-trifluoroethyl)quinazolin-4-yl]-2,7-diazaspiro[3.5]nonan-7-yl}methyl)-1h-indole-2-carbonitrile
| Molecular Weight | 617.7 g/mol |
|---|---|
| Molecular Formula | C33H34F3N7O2 |
| XLogP3 | 4.7 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 6 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 99.3 |
| Heavy Atom Count | 45 |
| Formal Charge | 0 |
| Complexity | 1120 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
79
PharmaCompass offers a list of Balomenib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Balomenib manufacturer or Balomenib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Balomenib manufacturer or Balomenib supplier.
A Balomenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Balomenib, including repackagers and relabelers. The FDA regulates Balomenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Balomenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Balomenib supplier is an individual or a company that provides Balomenib active pharmaceutical ingredient (API) or Balomenib finished formulations upon request. The Balomenib suppliers may include Balomenib API manufacturers, exporters, distributors and traders.
Balomenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Balomenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Balomenib GMP manufacturer or Balomenib GMP API supplier for your needs.
A Balomenib CoA (Certificate of Analysis) is a formal document that attests to Balomenib's compliance with Balomenib specifications and serves as a tool for batch-level quality control.
Balomenib CoA mostly includes findings from lab analyses of a specific batch. For each Balomenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Balomenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Balomenib EP), Balomenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Balomenib USP).
